Goal Reached Thanks to every supporter — we hit 100%!

Goal: 1000 CNY · Raised: 1359 CNY

100%

NemoClaw — Vulnerabilities & Security Advisories 14

All 14 CVE vulnerabilities found in NemoClaw, with AI-generated Chinese analysis, references, and POCs.

This page catalogs known Common Weakness Enumerations (CWE) associated with NemoClaw, a software product developed by its respective vendor. It serves as a centralized repository for security researchers, system administrators, and developers seeking to understand the specific flaw types that have been identified within this application environment. The current collection aggregates vulnerability data spanning multiple years, capturing the historical evolution of security issues reported since the product's initial release through to the most recent patches and advisories. This comprehensive timeframe allows for the analysis of long-term security trends and the identification of recurring problem areas within the codebase or architecture. Visitors to this page can effectively track the vendor’s official security advisories and patch release cycles to stay informed about critical updates. Users can also gain a deeper understanding of specific weakness classes, such as injection flaws or permission mishandling, by examining how they manifest in real-world scenarios within NemoClaw. Furthermore, the database facilitates the lookup of a product’s complete vulnerability history, enabling teams to assess risk exposure and prioritize remediation efforts based on verified incident records. By correlating weakness types with product versions, stakeholders can make more informed decisions regarding upgrades, configuration hardening, or migration strategies to mitigate known risks. This resource aims to provide transparent, structured, and actionable security intelligence without overwhelming the reader with raw data dumps or unverified claims.

Vendor: NVIDIA

All 14 known CVE vulnerabilities affecting NemoClaw with full Chinese analysis, references, and POCs where available.